Skip to content
Open menu

Prostate cancer active surveillance

Modern up-to-date radiotherapy methods cause a man so few adverse effects that as a rule, there is no longer any need for active follow-up for prostate cancer.

What is active surveillance of prostate cancer?

Active surveillance has long been one of the treatment options for men with low-risk localised prostate cancer. Frequently, this option has been chosen, because the side effects of prostate cancer treatment have been thought to decrease a man’s quality of life during his lifetime more than the cancer itself would. While under active surveillance, the patient undergoes regular examinations and tests, and if the cancer shows any signs of advancing, the need for treatment will be re-evaluated.

Active surveillance or immediate treatment of prostate cancer?

Active surveillance, however, involves a risk of cancer progression, as one cannot know for sure, which of the localised cancers stay local, and which will possibly become aggressive and begin to spread. Even recent research results (Hamdy et al. 2016) have suggested that the active monitoring of prostate cancer is associated with higher incidences of disease progression and metastases than is immediate treatment. Regular surveillance biopsies also involve a risk of infection. Moreover, the high number of tests tend to increase the surveillance costs.

Today, the fact in favour of the immediate treatment of localised prostate cancer is that the use of modern tissue-internal or external radiotherapy minimises the adverse effects of the treatment. In other words, the man’s quality of life remains as good as possible, while simultaneously, it is possible to treat the cancer efficiently. The most advanced radiotherapy techniques have not even been found to involve a risk of secondary cancers.

Active surveillance at Docrates Cancer Center

If active surveillance is the best option, at Docrates Cancer Center it can be arranged individually tailored. In active surveillance, decisions are always made after a thorough discussion where the benefits and risks of surveillance are weighed. At Docrates, the discussion is attended by the patient and his family and close friends and, as necessary, a urologist and an oncologist, so that the overall understanding is as comprehensive as possible and the patient knows exactly what his situation is and how to proceed.

Active surveillance includes:

  • Regular examinations: PSA testing every few months, regular MRI scans and, if necessary, new biopsies
  • Reassessment of the need for treatment: If the patient’s PSA levels increase at a rapid rate, MRI scans show that the cancer is advancing or a new biopsy indicates that the prostate cancer has become more aggressive, the need for treatment will be reassessed together with the patient.

Read more

Breast reconstruction surgery means meticulous craftsmanship by experienced surgeons

Reconstructing a removed breast is part of the treatment path of many breast cancer patients. The goal of the surgery...

Read more

Chief Clinical Director of Docrates Cancer Center: “Genetic information is an essential part of modern cancer care”

New forms of treatment based on molecular diagnostics enable more and more patients to completely recover from cancer, and make...

Customer message 3. September, 2024

With a transaction signed on 2 September 2024, Mehiläinen has acquired Docrates Ltd, as a result of which Docrates Cancer...

The competition authority issues its decision on the merger of Mehiläinen and Docrates Cancer Center

On 27, August 2024, the Finnish Competition and Consumer Authority (FCCA) approved the merger of Mehiläinen and Docrates Cancer Center....

Why come to Docrates Cancer Center?

  • Top cancer experts and effective treatments without delay.
  • Individual care. You have your own care team - your doctor and your nurse.
  • Front line cancer treatment. Latest medical technology combined with proven expertise in cancer care.
  • Experience in treating international patients from over 60 countries. Multilingual personnel.
+358 10 773 2010

Contact us!

Mon-Thu 8:00-18:00, Fri 8:00-16:00